L’infarctus du myocarde (IDM) résulte des complications de l’athérosclérose, dont le développement serait initié par une dysfonction endothéliale, s’accompagnant d’un état de stress oxydant. Le fer interagirait dans cette pathogenèse à différents niveaux et aurait également un rôle majeur dans la survenue de la dysfonction endothéliale. L’hepcidine et l’érythroferrone (découverte auparavant sous le nom de myonectine/CTRP 15), participeraient dans la régulation de certaines étapes du métabolisme du fer. La diméthyl-arginine asymétrique (ADMA), marqueur de dysfonction endothéliale, est associée à la plupart des facteurs de risque cardiovasculaire. Son stéréo-isomère, la diméthyl-arginine symétrique (SDMA), a une élimination exclusivement rénale et est considéré comme un puissant marqueur de fonction rénale.Nous nous sommes proposés d’étudier, chez des patients en phase aiguë d’IDM, la signification des paramètres traditionnels du statut du fer, des protéines impliquées dans la régulation du fer, l’hepcidine et la myonectine, ainsi que des dérivés méthylés de la L-arginine, l’ADMA et la SDMA.Dans notre première étude prospective, nous observons que les valeurs de SDMA, et dans une moindre mesure celles d'ADMA, sont associées à la glycémie d'admission et pourraient donc exercer des actions biologiques indépendantes de la fonction rénale. Notre second travail suggère que les patients présentant de l’insuffisance cardiaque à la phase aiguë de l’IDM sont caractérisés par une anémie et un certain degré de carence en fer. Le dosage des nouveaux biomarqueurs de la régulation du métabolisme du fer, l'hepcidine et la myonectine a montré une tendance à l’augmentation de ces taux sériques chez ces patients en lien avec une augmentation de la CRP. Ainsi nos travaux laissent entrevoir les liens qui uniraient, à la phase aiguë de l’infarctus du myocarde, ces nouveaux biomarqueurs régulateurs du métabolisme du fer aux conséquences fonctionnelles des pathologies cardiovasculaires, notamment en termes d’anémie et d’insuffisance cardiaque. / Myocardial infarction (MI) is mostly caused by complications of atherosclerosis, whose the development would be initiated by a dysfunction of the vascular endothelium, characterized by an inflammatory condition and oxidative stress.In this pathogenesis, iron interacts at different levels and also has a major role in the development of endothelial dysfunction. Hepcidin and erythroferrone (discovered earlier as the myonectin/CTRP 15) participate in a major way in regulating certain stages of iron metabolism.Asymmetric dimethylarginine (ADMA), a marker of endothelial dysfunction is associated with most cardiovascular risk factors. Symmetrical dimethyl-arginine (SDMA), its stereoisomer, has an exclusively renal elimination and is considered as a powerful renal function marker.We aimed to study, in patients with acute MI, the meaning of the "traditional" status iron parameters, two proteins involved in the regulation of iron, hepcidin and myonectin, as well as the two L-arginine derivatives, ADMA and SDMA. In our first prospective study, we observe that, in patients with acute MI, the values of SDMA, and only weakly ADMA, are associated with admission blood glucose, beyond traditional dimethylarginine determinants and may therefore have biological activity beyond renal function.Our second work suggests that patients with heart failure in the acute phase of MI present more frequently anemia and a certain degree of iron deficiency. New iron metabolism regulators biomarkers, hepcidin and myonectin showed a trend toward an increase in the serum levels in these patients characterized by an increase in CRP.Thus, our work suggests the links between these new regulators of iron metabolism in acute MI with functional consequences of cardiovascular diseases, particularly in terms of anemia and heart failure.

INTRODUÇÃO: O Infarto agudo do miocárdio (IAM) é infrequente em indivíduos jovens (<45 anos) e está associado à história familiar precoce de doença cardiovascular.OBJETIVO: O presente estudo descreveu o perfil sócio-demográfico e os fatores de risco cardiovascular de indivíduos com diagnóstico de IAM < 45 anos de idade e seus familiares de primeiro grau. Avaliou-se também a relação de parâmetros clínico-laboratoriais de acordo com a extensão angiográfica da doença arterial coronária (DAC) dos casos índices (doença uniarterial vs. multiarterial) e dos seus respectivos familiares.MÉTODOS: Estudo transversal realizado de novembro de 2010 a janeiro de 2015 em hospital terciário em Fortaleza, Ceará. Foram incluídos 103 casos índices e 166 familiares de primeiro grau que não apresentavam suspeita de hipercolesterolemia familiar. Estes foram comparados com 111 indivíduos assintomáticos e sem história familiar de DAC pareados para sexo e idade. Foram avaliados os parâmetros clínicos e laboratoriais dos 3 grupos. Os dados foram estudados por análises uni e multivariadas. RESULTADOS:O grupo casos apresentou maior prevalência de tabagismo (57,3 vs. 28,6%, p < 0,001), diabete melito tipo 2 - DM2 (43,4 vs. 19,5%, p < 0,001) e hipertensão arterial sistêmica - HAS (42,7 vs. 19%, p < 0,001) quando comparado aos familiares pareados para sexo e idade. Da mesma forma, os casos, quando comparados ao grupo controle, apresentaram, além destes fatores, concentrações mais elevadas de triglicerídeos (192 ± 75 vs. 140±74mg/dL, p < 0,001), menores concentrações de HDL-c (36 ± 12 vs. 48 ± 14mg/dL, p < 0,001) e uma maior prevalência de síndrome metabólica -SM (82,2 vs. 36%, p<0,001). Observou-se que 50,5% dos casos tinham acometimento multiarterial. Após análise multivariada, a HAS (p=0,030) e o DM2 (p=0,028) associaram-se de forma independente à DAC multiarterial. Quando comparados ao grupo controle, os familiares apresentaram maior prevalência de tabagismo (29,5 vs. 6,3%, p < 0,001), DM2 (19,9 vs. 1,8%, p < 0,001), pré-diabetes (40,4 vs. 27%, p < 0,024) e SM (64,7 vs. 36% p < 0,001). Foram observadas aindaconcentrações mais baixas de HDL-c (39±10 vs. 48 ± 14mg/dL, p < 0,001), valores mais elevados de triglicerídeos (179 ± 71 vs. 140 ± 74mg/dL, p = 0,002), LDL-c (122±37 vs. 113±36mg/dL, p = 0,031) e colesterol não-HDL (157 ± 43 vs. 141 ± 41mg/dL, p = 0,004) nos familiares. Não houve diferenças entre familiares e controles quanto ao IMC (p=0,051). Os familiares também apresentaram maior prevalência do risco calculado como alto/intermediário de acordo com o escore de Framingham (82,7 vs. 2,6%, p < 0,001) em relação aos controles. Os valores de TSH foram maiores, mesmo dentro do valor de referência do método, no grupo de casos (2,6 ± 1,6 vs. 1,9 ± 1,0 mUI/L, p < 0,001) e familiare (2,4±1,6 vs. 1,9 ± 1,0 mUI/L, p=0,002) em relação aos controles. CONCLUSÃO: Evidenciou-seelevada prevalência de fatores de risco cardiovascular, principalmente a SM, dislipidemia aterogênica, DM2, HAS e tabagismo em casos e familiares de primeiro grau de indivíduos com IAM < 45 anos. A HAS e o DM2 associaram-se à maior extensão angiográfica da DAC / BACKGROUND: The acute myocardial infarction (AMI) is uncommon in young individuals ( < 45 years), and is associated with premature family history of cardiovascular disease. OBJECTIVE: This study described the socio-demographic and cardiovascular risk factors of both subjects with AMI < 45 years of age and their first-degree relatives. The association of clinical and laboratory parameters with the angiographic extension of coronary artery disease (CAD) of index cases (single-vessel vs. multivessel disease) and in their respective relatives was also evaluated. METHODS: Cross-sectional study conducted from November 2010 to January 2015 in a tertiary hospital in Fortaleza, Ceara. One hundred and three index cases and 166 first-degree relatives without suspicion of familial hypercholesterolemia were included. These were compared with 111 asymptomatic individuals without family history of CAD matched for sex and age. Clinical and laboratory parameters of the 3 groups were evaluated. Associations were tested by univariate and multivariate analysis. RESULTS: AMI cases presented a higher prevalence of smoking (57.3% vs. 28.6%, p < 0.001), type 2 diabetes mellitus -DM2 (43.4 vs. 19.5%, p < 0.001), and hypertension (42.7 vs. 19%, p < 0.001) when compared to relatives matched for sex and age. Likewise cases, when compared to controls showed in addition higher triglycerides (192 ± 75mg/dL vs. 140 ± 74mg/dL, p < 0.001), lower HDL-C (36 ± 12mg/dL vs. 48±14mg/dL, p < 0.001), and a greater prevalence of the metabolic syndrome-MS (82.2% vs. 36%, p < 0.001). Multivessel disease was found in 50.5% of cases. After multivariate analysis, hypertension (p=0.030), and DM2 (p=0.028) were independently associated with multivessel disease. First-degree relatives showed a greater prevalence of smoking (29.5% vs. 6.3%, p < 0.001), DM2 (19.9% vs. 1.8%, p < 0.001), pre-diabetes (40.4 % vs. 27%, p < 0.024) and MS (64.7% vs. 36%, p < 0.001), when compared to controls. Lower HDL-c (39±10mg/dL vs. 48 ± 14mg/dL, p < 0.001), higher triglycerides (179±71mg/dL vs. 140±74mg/dL, p=0.002), higher LDL-C (122 ± 37mg/dL vs. 113 ± 36mg/dL, p=0.031) and non-HDL cholesterol (157 ± 43 vs. 141±41mg/dL, p=0.004) were found in relatives than controls. There was no difference in BMI (p=0.051) between the groups. Relatives also showed a higher prevalence of high/intermediate calculated coronary heart disease risk according to the Framingham risk score (82.7% vs. 2.6%, p < 0.001). TSH levels even within the reference value method were higher in AMI patients (2.6 ± 1.6mUI/mL, p < 0.001) and relatives (2.4 ± 1.6mUI/mL, p=0.002) in comparison with controls 1.9±1.0mUI/mL). CONCLUSION: A high prevalence of risk factors mainly MS, atherogenic dyslipidemia, type 2 DM, hypertension and smoking were encountered in cases and first-degree relatives of individuals with AMI < 45 years. Hypertension and DM2 were associated with greater angiographic extent of coronary artery disease

Introduction: Ventricular arrhythmias (VAs) are common after an acute coronary syndrome (ACS) and are associated with worse clinical outcomes. However, little is known about recent trends in their occurrence, their association with serum glucose levels, and their psychological impact in ACS setting. Methods: We examined 25-year (1986-2011) trends in the incidence rates (IRs) and hospital case-fatality rates (CFRs) of VAs, and the association between serum glucose levels and VAs in patients with an acute myocardial infarction (AMI) in the Worcester Heart Attack Study. Lastly, we examined the relationship between in-hospital occurrence of VAs and 12-month progression of depression and anxiety among hospital survivors of an ACS in the longitudinal TRACE-CORE study. Results: We found the IRs declined for several major VAs between 1986 and 2011while the hospital CFRs declined in both patients with and without VAs over this period. Elevated serum glucose levels at hospital admission were associated with a higher risk of developing in-hospital VAs. Occurrence of VAs, however, was not associated with worsening progression of symptoms of depression and/or anxiety over a 12-month follow-up period in patients discharged after an ACS. Conclusions: The burden and impact of VAs in patients with an AMI has declined over time. Elevated serum glucose levels at hospital admission may serve as a predictor for in-hospital occurrence of serious cardiac arrhythmias. In-hospital occurrence of VAs may not be associated with worsening progression of symptoms of depression and anxiety in patients with an ACS.

Ziel der Studie war es zu analysieren, welchen Einfluss eine angiographisch sichtbare Kollateralisierung vor Revaskularisation bei Patienten mit einem akuten ST-Elevations-Myokardinfarkt (STEMI) und primärer perkutaner Koronarintervention (PCI) auf verschiedene in der kardialen Magnetresonanztomographie messbare Parameter und auf die klinische Prognose hat. Es wurden 235 Patienten mit STEMI und einem Symptombeginn <12 Stunden in die Analyse eingeschlossen. Alle Patienten wiesen einen funktionell insuffizienten antegraden Fluss in der Infarktarterie auf. Die Patienten wurden in zwei Gruppen unterteilt: Gruppe A mit fehlender oder nur geringer Kollateralversorgung (n=166) und Gruppe B mit einer signifikanten Kollateralisierung (n=69). Es wurden Infarktgröße, mikrovaskuläre Obstruktion und linksventrikuläre Funktion mittels Magnetresonanztomographie im Median 3 Tage nach dem Infarktereignis bestimmt sowie die Patienten über einen Zeitraum von >2 Jahren nachbeobachtet. Das Ausmaß der frühen mikrovaskulären Obstruktion war in Gruppe B signifikant geringer (3,3% gegenüber 2,1% der linksventrikuläre Masse, p = 0,009). Die mittels maximaler Kreatinkinase-MB-Ausschüttung gemessene Infarktgröße war in Gruppe B kleiner (p=0,02). Bei 227 Patienten (97%) wurde nach im Median 2,2 Jahren eine klinische Verlaufskontrolle durchgeführt. Insgesamt starben während des Kontrollzeitraums 25 Patienten: 22 Patienten (13,8%) der Gruppe A mit fehlender oder nur schwacher Kollateralisierung und 3 Patienten (4,4%) der Gruppe B mit signifikanter Kollateralversorgung vor Behandlungsbeginn (p=0,04). In Gruppe A traten 12 (7,5%) nicht-tödliche Reinfarkte auf im Vergleich zu 2 (2,9%) in Gruppe B (p=0,18). Ein kombinierter Endpunkt aus Tod oder nicht-tödlichem Reinfarkt trat in Gruppe B signifikant seltener auf als in Gruppe A (p=0,02). Zusammenfassend lässt sich formulieren, dass gut ausgebildete Kollateralgefäße vor einer Revaskularisation mittels PCI bei Patienten mit akuten STEMI mit einer schützenden Wirkung auf die koronare Mikrozirkulation und einem besseren Langzeit-Überleben assoziiert sind.:1 BIBLIOGRAPHISCHE BESCHREIBUNG 2 ABKÜRZUNGSVERZEICHNIS 3 EINFÜHRUNG 4 AUFGABENSTELLUNG 5 MATERIALIEN UND METHODEN 5.1 Überblick über das Studiendesign 5.2 Koronarintervention 5.3 Enzymatische Infarktgröße 5.4 Kardiale Magnetresonanztomographie 5.4.1 Linksventrikuläre Volumina und Ejektionsfraktion 5.4.2 Infarktgröße 5.4.3 Mikrovaskuläre Obstruktion 5.5 Klinisches Follow-up 5.6 Statistik 6 ERGEBNISSE 6.1 Patientencharakteristika 6.2 Enzymatische Infarktgröße 6.3 Magnetresonanztomographie 6.4 Klinische Ereignisse im Langzeitverlauf 6.5 Prädiktoren klinischer Ereignisse 6.5.1 Univariate Cox-Regressions-Analyse 6.5.2 Multivariate Cox-Regressions-Analyse 6.6 Klinische Ergebnisse in Abhängigkeit von der Zeit zwischen Symptombeginn und Reperfusion 6.7 Magnetresonanztomographische Ergebnisse in Abhängigkeit von der Zeit zwischen Symptombeginn und Reperfusion 7 DISKUSSION 7.1 Limitationen 8 ZUSAMMENFASSUNG DER ARBEIT 9 LITERATURVERZEICHNIS 10 DANKSAGUNG 11 ERKLÄRUNG ÜBER DIE EIGENSTÄNDIGE ABFASSUNG DER ARBEIT 12 LEBENSLAUF 13 PUBLIKATIONEN

Ziel der Studie war es zu analysieren, welchen Einfluss eine angiographisch sichtbare Kollateralisierung vor Revaskularisation bei Patienten mit einem akuten ST-Elevations-Myokardinfarkt (STEMI) und primärer perkutaner Koronarintervention (PCI) auf verschiedene in der kardialen Magnetresonanztomographie messbare Parameter und auf die klinische Prognose hat. Es wurden 235 Patienten mit STEMI und einem Symptombeginn <12 Stunden in die Analyse eingeschlossen. Alle Patienten wiesen einen funktionell insuffizienten antegraden Fluss in der Infarktarterie auf. Die Patienten wurden in zwei Gruppen unterteilt: Gruppe A mit fehlender oder nur geringer Kollateralversorgung (n=166) und Gruppe B mit einer signifikanten Kollateralisierung (n=69). Es wurden Infarktgröße, mikrovaskuläre Obstruktion und linksventrikuläre Funktion mittels Magnetresonanztomographie im Median 3 Tage nach dem Infarktereignis bestimmt sowie die Patienten über einen Zeitraum von >2 Jahren nachbeobachtet. Das Ausmaß der frühen mikrovaskulären Obstruktion war in Gruppe B signifikant geringer (3,3% gegenüber 2,1% der linksventrikuläre Masse, p = 0,009). Die mittels maximaler Kreatinkinase-MB-Ausschüttung gemessene Infarktgröße war in Gruppe B kleiner (p=0,02). Bei 227 Patienten (97%) wurde nach im Median 2,2 Jahren eine klinische Verlaufskontrolle durchgeführt. Insgesamt starben während des Kontrollzeitraums 25 Patienten: 22 Patienten (13,8%) der Gruppe A mit fehlender oder nur schwacher Kollateralisierung und 3 Patienten (4,4%) der Gruppe B mit signifikanter Kollateralversorgung vor Behandlungsbeginn (p=0,04). In Gruppe A traten 12 (7,5%) nicht-tödliche Reinfarkte auf im Vergleich zu 2 (2,9%) in Gruppe B (p=0,18). Ein kombinierter Endpunkt aus Tod oder nicht-tödlichem Reinfarkt trat in Gruppe B signifikant seltener auf als in Gruppe A (p=0,02). Zusammenfassend lässt sich formulieren, dass gut ausgebildete Kollateralgefäße vor einer Revaskularisation mittels PCI bei Patienten mit akuten STEMI mit einer schützenden Wirkung auf die koronare Mikrozirkulation und einem besseren Langzeit-Überleben assoziiert sind.:1 BIBLIOGRAPHISCHE BESCHREIBUNG 2 ABKÜRZUNGSVERZEICHNIS 3 EINFÜHRUNG 4 AUFGABENSTELLUNG 5 MATERIALIEN UND METHODEN 5.1 Überblick über das Studiendesign 5.2 Koronarintervention 5.3 Enzymatische Infarktgröße 5.4 Kardiale Magnetresonanztomographie 5.4.1 Linksventrikuläre Volumina und Ejektionsfraktion 5.4.2 Infarktgröße 5.4.3 Mikrovaskuläre Obstruktion 5.5 Klinisches Follow-up 5.6 Statistik 6 ERGEBNISSE 6.1 Patientencharakteristika 6.2 Enzymatische Infarktgröße 6.3 Magnetresonanztomographie 6.4 Klinische Ereignisse im Langzeitverlauf 6.5 Prädiktoren klinischer Ereignisse 6.5.1 Univariate Cox-Regressions-Analyse 6.5.2 Multivariate Cox-Regressions-Analyse 6.6 Klinische Ergebnisse in Abhängigkeit von der Zeit zwischen Symptombeginn und Reperfusion 6.7 Magnetresonanztomographische Ergebnisse in Abhängigkeit von der Zeit zwischen Symptombeginn und Reperfusion 7 DISKUSSION 7.1 Limitationen 8 ZUSAMMENFASSUNG DER ARBEIT 9 LITERATURVERZEICHNIS 10 DANKSAGUNG 11 ERKLÄRUNG ÜBER DIE EIGENSTÄNDIGE ABFASSUNG DER ARBEIT 12 LEBENSLAUF 13 PUBLIKATIONEN

Background: Alcohol consumption has been causally related to the incidence of coronary heart disease, but the role of alcohol before the event has not been explored in depth. This study tested the hypothesis that heavy drinking (binge drinking) increases the risk of subsequent acute myocardial infarctions (AMI), whereas light to moderate drinking occasions decrease the risk. Methods: Case-crossover design of 250 incident AMI cases in Switzerland, with main hypotheses tested by conditional logistic regression. Results: Alcohol consumption 12 h before the event significantly increased the risk of AMI (OR 3.1; 95% CI 1.4–6.9). Separately, the effects of moderate and binge drinking before the event on AMI were of similar size but did not reach significance. In addition, AMI patients showed more binge drinking than comparable control subjects from the Swiss general population. Conclusions: We found no evidence that alcohol consumption before the event had protective effects on AMI. Instead, alcohol consumption increased the risk. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

Indiana University-Purdue University Indianapolis (IUPUI) / A hierarchy of endothelial colony forming cells (ECFCs) with different levels of proliferative potential has been identified in human circulating blood and blood vessels. High proliferative potential ECFCs (HPP-ECFCs) display properties (robust proliferative potential in vitro and vessel-forming ability in vivo) consistent with stem/progenitor cells for the endothelial lineage. Corneal endothelial cells (CECs) are different from circulating and resident vascular endothelial cells (ECs). Whereas systemic vascular endothelium slowly proliferates throughout life, CECs fail to proliferate in situ and merely expand in size to accommodate areas of CEC loss due to injury or senescence. However, we have identified an entire hierarchy of ECFC resident in bovine CECs. Thus, this study provides a new conceptual framework for defining corneal endothelial progenitor cell potential. The identification of persistent corneal HPP-ECFCs in adult subjects might contribute to regenerative medicine in corneal transplantation. While human cord blood derived ECFCs are able to form vessels in vivo, it is unknown whether they are committed to an arterial or venous fate. We have demonstrated that human cord blood derived ECFCs heterogeneously express gene transcripts normally restricted to arterial or venous endothelium. They can be induced to display an arterial gene expression pattern after vascular endothelial growth factor 165 (VEGF165) or Notch ligand Dll1 (Delta1ext-IgG) stimulation in vitro. However, the in vitro Dll1 primed ECFCs fail to display significant skewing toward arterial EC phenotype and function in vivo upon implantation, suggesting that in vitro priming is not sufficient for in vivo specification. Future studies will determine whether ECFCs are amenable to specification in vivo by altering the properties of the implantation microenvironment. There is emerging evidence suggesting that the concentration of circulating ECFCs is closely related to the adverse progression of cardiovascular disorders. In a pig model of acute myocardial ischemia (AMI), we have demonstrated that AMI rapidly mobilizes ECFCs into the circulation, with a significant shift toward HPP-ECFCs. The exact role of the mobilized HPP-ECFCs in homing and participation in repair of the ischemic tissue remains unknown. In summary, these studies contribute to an improved understanding of ECFCs and suggest several possible therapeutic applications of ECFCs.

La première partie de cette thèse porte sur l'étude du no-reflow ou obstruction microvasculaire en IRM cardiaque. Dans une première étude, nous avons mesuré l'incidence du no-reflow dans une population de 25 patients pris en charge pour infarctus du myocarde sans sus-décalage du segment ST. Nous avons trouvé que 32% de ces patients présentaient un no-reflow et que la présence de no-reflow était associée à une taille d'infarctus significativement plus importante ainsi qu'une élévation plus importante des enzymes cardiaques. Dans une deuxième étude nous avons comparé la performance diagnostique du myocardial blush grade (MBG) pour le diagnostic du no-reflow avec l'IRM cardiaque sur les séquences de rehaussement tardif post-gadolinium. Cette étude a été réalisée dans une population de 39 patients pris en charge pour un premier épisode de STEMI. Nous avons trouvé que le MBG sous-estimait la présence de no-reflow à la phase aiguë de l'infarctus après reperfusion optimale en comparaison avec l'IRM. La deuxième partie de cette thèse concerne la quantification de l'infarctus du myocarde en IRM cardiaque de rehaussement tardif post-gadolinium. Nous avons comparé une technique d'évaluation semi-quantitative visuelle rapide avec la planimétrie manuelle classique sur une population de 103 patients pris en charge pour syndrome coronarien aigu. La taille de l'infarctus était évaluée par ces deux méthodes en IRM cardiaque réalisée 4 jours après admission. Nous avons trouvé une excellente corrélation et un bon niveau de concordance entre les deux méthodes d'évaluation de la taille d'infarctus, avec des temps de posttraitements beaucoup plus courts pour l'analyse visuelle rapide. Enfin, la troisième partie de cette thèse aborde le sujet de l'utilisation de l'IRM cardiaque comme outil de mesure dans les essais thérapeutiques sur la reperfusion myocardique. Nous avons utilisé l'IRM cardiaque pour évaluer l'efficacité de l'utilisation de la cyclosporine A à la phase aigüe de l'infarctus reperfusé et son effet sur remodelage ventriculaire à 6 mois. Dans cette étude 28 patients ont été étudiés en IRM cardiaque 5 jours et 6 mois après un infarctus du myocarde. Nous avons trouvé une persistance de la réduction significative de 23% de taille de l'infarctus à 6 mois dans le groupe traité par cyclosporine par rapport au groupe contrôle. Il n'y avait pas d'effet négatif de la cyclosporine A sur le processus de remodelage ventriculaire gauche / We assessed the presence and extent of microvascular obstruction (MVO) and its relationship with infarct size and left ventricular (LV) functional parameters after acute non-ST elevated myocardial infarction (NSTEMI). 25 patients with first acute NSTEMI underwent a complete cardio magnetic resonance (CMR) study 72 hours after admission. MO was detected in 32% of patients and was significantly associated with a larger infarct size. There were no significant difference between both groups for the LV functional parameters but patients with MO showed a higher troponin-I and CK release. We studied the relation between Myocardial Blush Grade (MBG) and gadolinium-enhanced CMR for the assessment of MVO in 39 patients with acute ST elevated myocardial infarction (STEMI) treated by primary PCI. No statistical relation was found between MBG and MVO extent at CMR (p=0.63). MBG underestimates MVO after an optimal revascularization in AMI compared to CMR.We compared the performance and post-processing time of a global visual scoring method to standard quantitative planimetry and we compared both methods to the peak values of myocardial biomarkers. 103 patients admitted with reperfused AMI to our intensive care unit had a complete CMR study 4±2 days after admission. There was an excellent correlation between quantitative planimetry and visual global scoring for the hyperenhancement extent’s measurement (r=0.94; y=1.093x+0.87; SEE=1.2; P<0.001) and there was also a good concordance between the two approaches with significantly shorter mean post-processing time for the visual scoring method. There was also significant levels of correlation between the enzymatic peak values and the visual global scoring method. The visual global scoring method allows a rapid and accurate assessment of the myocardial global delayed enhancement. This study examined the effect of a single dose of cyclosporine A used at the time of reperfusion, on LV remodeling and function by cardiac magnetic resonance (CMR) in the early days and 6 months after AMI.28 patients of the original cyclosporine A study had an acute (day 5) and a follow-up (6 months) CMR study. There was a persistent 23% reduction of the absolute infarct size at 6 months without any dementrial effect in the cyclosporine A group compared with the control group of patients. Cyclosporine A used at the moment of AMI reperfusion persistently reduces infarct size and does not have a detrimental effect on LV remodeling

No description available.

BackgroundThe prompt seeking of medical care after the onset of symptoms suggestive of acute coronary syndromes (ACS)/acute myocardial infarction (AMI) is associated with the receipt of coronary reperfusion therapy, and effective cardiac medications in patients with an ACS/AMI and is crucial to reducing mortality and the risk of serious clinical complications in these patients. Despite declines in important hospital complications and short-term death rates in patients hospitalized with an ACS/AMI, several patient groups remain at increased risk for these adverse outcomes, including women and the elderly. However, recent trends in age and sex differences in extent of pre-hospital delay, hospital management practices, and short-term outcomes associated with ACS/AMI remain unexplored. The objectives of this study were to examine the overall magnitude, and changing trends therein, of age and sex differences in duration of pre-hospital delay (1986-2005), hospital management practices (1999-2007), and short-terms outcomes (1975-2005) in patients hospitalized with ACS/AMI. MethodsData from 13,663 residents of the Worcester, MA, metropolitan area hospitalized at all greater Worcester medical centers for AMI 15 biennial periods between 1975 and 2005 (Worcester Heart Attack Study), and from 50,096 patients hospitalized with an ACS in 106 medical centers in 14 countries participating in the Global Registry of Acute Coronary Events (GRACE) between 2000 and 2007 were used for this investigation. Results In comparison with men years, patients in other age-sex strata exhibited significantly longer pre-hospital delay, with the exception of women < 65 years; had a significantly lower odds of receiving aspirin, angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), beta blockers, statins, and undergoing coronary artery bypass graft surgery (CABG) surgery or percutaneous coronary intervention (PCI), and were significantly more likely to develop atrial fibrillation, cardiogenic shock, heart failure, and to die during hospitalization and in the first 30 days after admission. There was a significant interaction between age and sex in relation to the use of several medications and the development of several of these outcomes; in patients Conclusions Our results suggest that the elderly were more likely to experience longer prehospital delay, were less likely to be treated with evidence-based treatments during hospitalization for acute coronary syndrome, and were more likely to develop adverse outcomes compared to younger persons. Younger women were less likely to be treated with effective treatments and were more likely to develop adverse outcomes compared with younger men while there was no sex difference in these outcomes. Interventions targeted at older patients, in particular, are needed to encourage these high-risk patients to seek medical care promptly to maximize the benefits of currently available treatment modalities. More targeted treatment approaches during hospitalization for ACS/AMI for younger women and older patients are needed to improve their hospital prognosis.